{"id":"immediate-switch-to-tdf-ftc-rpv","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Renal impairment (TDF-related)"},{"rate":null,"effect":"Bone density loss (TDF-related)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TDF (tenofovir disoproxil fumarate) is a nucleotide reverse transcriptase inhibitor, FTC (emtricitabine) is a nucleoside reverse transcriptase inhibitor, and RPV (rilpivirine) is a non-nucleoside reverse transcriptase inhibitor. Together they target different mechanisms of HIV replication, reducing viral load in treatment-experienced or treatment-naive patients.","oneSentence":"A fixed-dose combination of three antiretroviral agents that inhibits HIV reverse transcriptase and integrase to suppress viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:48:18.185Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naive or treatment-experienced adults"}]},"trialDetails":[{"nctId":"NCT02042001","phase":"PHASE4","title":"Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects","status":"COMPLETED","sponsor":"Azienda Ospedaliera San Gerardo di Monza","startDate":"2015-07-01","conditions":"Impaired Cognition, Depression/Anxiety, Poor Quality Sleep","enrollment":74}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Eviplera (r)"],"phase":"marketed","status":"active","brandName":"Immediate switch to TDF/FTC/RPV","genericName":"Immediate switch to TDF/FTC/RPV","companyName":"Azienda Ospedaliera San Gerardo di Monza","companyId":"azienda-ospedaliera-san-gerardo-di-monza","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A fixed-dose combination of three antiretroviral agents that inhibits HIV reverse transcriptase and integrase to suppress viral replication. Used for HIV-1 infection in treatment-naive or treatment-experienced adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}